Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ivesa (firmonertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Allist, ArriVent

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B
EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B	firmonertinib Sensitive: B - Late Trials firmonertinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2	icotinib + firmonertinib Sensitive: C2 – Inclusion Criteria icotinib + firmonertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	icotinib + firmonertinib Sensitive: C3 – Early Trials icotinib + firmonertinib Sensitive : C3	icotinib + firmonertinib Sensitive: C3 – Early Trials icotinib + firmonertinib Sensitive : C3
EGFR N771_P772insH	Non Small Cell Lung Cancer	EGFR N771_P772insH	Non Small Cell Lung Cancer	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4
EGFR exon 20 insertion	Lung Adenocarcinoma	EGFR exon 20 insertion	Lung Adenocarcinoma	anlotinib + firmonertinib Sensitive: C4 – Case Studies anlotinib + firmonertinib Sensitive : C4	anlotinib + firmonertinib Sensitive: C4 – Case Studies anlotinib + firmonertinib Sensitive : C4
EGFR N771_P772insVal	Lung Adenocarcinoma	EGFR N771_P772insVal	Lung Adenocarcinoma	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4
EGFR S768_D770dupSVD	Lung Adenocarcinoma	EGFR S768_D770dupSVD	Lung Adenocarcinoma	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4	firmonertinib Sensitive: C4 – Case Studies firmonertinib Sensitive : C4